1 Title Page

- 2 Genomic and epigenomic evolution of metastatic prostate cancer: the first warm
- 3 autopsy in China

4

- 5 Wenhui Zhang^{1†}, Yan Wang^{1†}, Min Qu^{1†}, Haoqing Shi^{1†}, Xin Lu¹, Qingsong Yang²,
- 6 Fang Liu², Tao Wang³, Ziwei Wang¹, Bijun Lian⁴, Ling Chen⁵, Xiaoyi Yin⁶, Yongwei
- 7 Yu⁷, Jing Li^{8,9,a*}, Xu Gao^{1,b*}, Zhuan Liao^{10,c*}

8

- 9 ¹ Department of Urology, Changhai Hospital, Second Military Medical University,
- 10 Shanghai 200433, China
- ² Department of Radiology, Changhai Hospital, Second Military Medical University,
- 12 Shanghai 200433, China
- 13 ³ Department of Urology, the First Affiliated Hospital of Zhengzhou University,
- 14 Zhengzhou, Henan 450052, China
- ⁴ Department of Urology, the 903rd PLA Hospital, Hangzhou, Zhejiang 310012,

16 China

- ⁵ Department of Oncology, Changhai Hospital, Second Military Medical University,
- 18 Shanghai 200433, China
- ⁶ Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Second
- 20 Military Medical University, Shanghai 200433, China

- ⁷ Department of Pathology, Changhai Hospital, Second Military Medical University,
- 22 Shanghai 200433, China
- ⁸ Shanghai Key Laboratory of Cell Engineering, Second Military Medical University,
- 24 Shanghai 200433, China
- ⁹ Department of Bioinformatics, Center for Translational Medicine, Second Military
- 26 Medical University, Shanghai 200433, China
- ¹⁰ Clinical Research Center, Changhai Hospital, Second Military Medical University,
- 28 Shanghai 200433, China
- 29
- 30 † These authors contributed equally to this work.
- 31 * Corresponding author.
- 32 a Department of Bioinformatics, Center for Translational Medicine, Second Military
- 33 Medical University, Shanghai 200433, China. Tel.+86 15801 966205; Fax: +86 21
- 34 8187 0033; E-mail address: ljing@smmu.edu.cn
- 35 b Department of Urology, Changhai Hospital, Second Military Medical University,
- 36 Shanghai 200433, China. Tel.+86 13501 655091; Fax: +86 21 3503 0006; E-mail
- 37 address: gaoxu.changhai@foxmail.com.
- 38 c Clinical Research Center, Changhai Hospital, Second Military Medical University,
- 39 Shanghai 200433, China. Tel.+86 13061 921980; Fax: +86 21 3116 1004; E-mail
- 40 address: zhuanleo@126.com.
- 41

42 Abstract

Background: The development and expansion of warm autopsy program have
important implications in dissecting the heterogeneity during cancer dissemination
and resistance. However, in China, the practice of warm autopsy has not yet been
officially launched and documented.

47 **Methods:** To explore and establish the procedures and standards for warm 48 autopsy in China, we followed the disease course of a male patient with terminal 49 metastatic prostate cancer. We assembled a multidisciplinary team to perform 50 warm autopsy immediately after death. Through longitudinal sampling from biopsy 51 and autopsy, we performed integrative and comprehensive genomic and 52 epigenomic analysis using multi-omics approaches.

Results: We traced the dynamic evolution and heterogeneity of this prostate tumor, and identified many critical driver events in both the original tumor and its disseminations. Truncated *CDKN1B* may result in downregulation of expression, which represent a key driver event in the metastatic progression of prostate cancer. We also delineated the congruence of genetic and epigenetic clonal evolution during tumor metastasis.

59 **Conclusions:** Our data and analysis elucidated the mechanisms and drivers 60 during metastasis, which represent a valuable resource for the study and 61 treatment of prostate cancer. We also call on more investigators to improve warm 62 autopsy of prostate cancer for clinical and experimental investigations.

63 Keywords: Clonal evolution; Intratumor heterogeneity; Prostate cancer;
64 Metastasis; Epigenetics.

65

66 Background

67 Prostate cancer is the one of the most common malignancies of men in China, and 68 the incidence and mortality rates are much higher than the average levels 69 worldwide¹. The majority of prostate cancer deaths are attributed to metastatic dissemination of the primary tumor^{2,3}. The collection and investigation of tumor 70 71 samples at multiple metastatic sites can be instrumental in dissecting the evolving 72 complexity of tumor metastasis. The needle biopsy is not practical for 73 simultaneously acquiring metastatic tumors from multiple sites of the same patient. 74 In contrast, multiple tissue harvesting by autopsy is an excellent way to collect 75 most tissues and preserve most viable samples.

76 The Autopsy Section investigates final diagnosis of the disease which caused the 77 death of a patient in clinic. In academic settings, autopsies provide an opportunity 78 for researchers and students to understand disease process by studying 79 postmortem tissues and the clinical record. An important function of an academic 80 autopsy service is to process tissues for research purposes. The advent of 81 "immediate" autopsy in 1976 enabled acquisition of inaccessible tissues and cells 82 for culturing⁴. The prototype of "warm autopsy" at an academic institution was developed in the 1980s⁵. After the stable and integrated infrastructure setting up 83

р5

84 for cells isolation, the purpose for rapid autopsy had been shifted to specimen biobanking⁶. In 2000, "warm autopsy" as a term has been defined as acquisition of 85 tissue samples through immediate autopsy shortly after death⁷. A team at 86 87 University of Michigan successfully collected 8 different tissue types from 14 warm 88 autopsy cases within 4 years, meeting the need of collecting high-quality primary 89 and metastatic tumor samples for molecular studies. 90 Today, with the advent of next-generation sequencing, warm autopsy represents 91 the next phase in modern pathology. Warm autopsy program has now been implemented in many countries⁸⁻¹⁰. However, the study of warm autopsy has 92 93 lagged behind in China. There is no documented program for this specific research 94 area in China to-date.

95 Here, we report the first, to our knowledge, warm autopsy in China. By performing 96 sequencing on eight metastatic tissues collected via warm autopsy from an 97 advanced prostate cancer patient, we revealed extensive intratumor heterogeneity 98 between different metastases, and delineated the congruence of genetic and 99 epigenetic clonal evolution. Our work developed the procedures and standards for 100 warm autopsy, and we call on Chinese urologists and oncologists to promote warm 101 autopsy of prostate cancer for clinical and experimental investigations.

102 Methods

103 Patient information and course of the disease

р6

104	A male patient in his 60s was diagnosed with prostate adenocarcinoma in January
105	2016. The transrectal ultrasound-guided prostate biopsy showed prostate cancer
106	(T3aN1Mx, tPSA: 20.166 ng/ml, Gleason Score: 5+5). The patient was started on
107	treatment with ADT and chemotherapy, after a short partial response (PSA
108	2.52ng/ml). Soon after the patient got into mCRPC. Left clavicle lymph node and
109	multiple vertebral metastases were detected by MRI in July 2016. Then the ADT
110	and chemotherapy were suspended, and collection of plasma and lymph node (LN)
111	biopsy was initiated for further treatment evaluation. Two months later, treatment
112	was switched to Vemurafenib due to a BRAF V600E mutation detected by the
113	ctDNA targeted sequencing. General deterioration then occurred, with disease
114	progression into cachexia (dyspnea, renal insufficiency and heart failure).
115	Treatment was stopped and the patient died on January 2017. Tumor samples for
116	sequencing were obtained from the primary prostate sites at diagnosis and
117	metastases at warm autopsy.

118 **Committee establishment**

With the support of the Changhai Warm Autopsy Team (CWAT) and Red Cross, the committee of warm autopsy was established, which consisted of a clinical care team (including urologists and oncologists), surgeons (including general surgeons, orthopedists, cardiothoracic surgeons, and neurosurgeons), pathologists, researchers (including translational medicine center and laboratory assistants), ethics board and the administrative unit (Fig 1). Patients diagnosed with end-stage

p7

125 CRPC were referred to the Urology Department of Shanghai Changhai Hospital. 126 The objectives and procedures for this study were explained to the patient carefully. 127 Permission for warm autopsy was obtained before the death, with consent 128 provided by the patient and the family members. After death, consent was 129 obtained by the family members with the witness by the operator and the ethics 130 committee. Written informed consent was obtained in accordance with Chinese legislation. Sample collection and study were approved by the ethical board at 131 132 Changhai Hospital (No: TMEC2014-001, No: CHEC2019-165).

133 Implementation of the warm autopsy

134 The body was sprayed with ethanol before operation. Then the operator 135 approached the internal organs through an "+ shaped" incision, up to the 136 collarbone, down to the pelvis, extend the middle route on both sides. The skin and 137 subcutaneous tissues were retracted from the thorax and abdomen, and the blood 138 and other body fluid were collected in the tubes. Around the warm autopsy 139 operator, there were 6 independent collection areas for tissue procurement and storage (Neurosurgery, Cardiothoracic, Urology, General Surgery, Orthopedic, 140 141 and Pathology biobank). Firstly, the urological operator resected the prostate, 142 urinary bladder, and pelvic lymph nodes in a manner similar to that of a 143 cystoprostatectomy. Then the kidneys, adrenal glands and ureters were resected 144 in a manner similar to that of a nephroureterectomy. Secondly, the breastplate was 145 removed by cardiothoracic surgeon. The heart, lungs, aorta and mediastinum were

р8

146 resected orderly. Meanwhile, the general surgeon reseed the stomach, liver, 147 gallbladder, pancreas, colon and retroperitoneal lymph nodes. Thirdly, the 148 orthopedist collected the bone metastases as well as the control tissues, and the 149 neurosurgeon collected the brain. The tissue was cut into approximately 150 10mm×10mm×20mm slice, which was divided into three contiguous aliquots for 151 the homology of purified DNA/RNA/protein. And we do triplication repeat to 152 guarantee the quality of tissue. Finally, tumor tissues from eight metastatic sites 153 and normal tissues from 23 anatomic sites were procured by warm autopsy. The 154 collection of normal tissues referenced the Genotype-Tissue Expression (GTEx) project¹¹, included kidney (cortex), ureter, bladder, testis, adrenal gland, brain 155 156 (cortex), brain (cerebellum), bone, heart (left ventricle), artery, breast, thyroid, esophagus (muscularis), stomach, pancreas, omentum, gallbladder, liver, colon, 157 158 ileum, jejunum, muscle, skin (suprapubic).

159 **Pathological evaluation of specimens and tissue storage**

All autopsy samples were immediately frozen in liquid nitrogen and stored at -80 °C. One primary sample (PB2) and seven fresh-frozen samples from warm autopsy except for bone (LV2M) were also stored in RNAlater (Ambion) for RNA extraction according to manufacturer protocol (Supplementary Table S1). Hematoxylin and eosin (H&E) stains were performed for thin slices of snap-frozen, OCT-embedded tissue blocks using standard techniques. Tumor staging and pathological grading were independently determined by two professional

uropathologists. Bone metastases were defined using emission computed
tomography (ECT). According to EAU guidelines, the diagnostic criteria for CRPC
were the castrate levels of serum testosterone < 50 ng/dL, or 1.7 nmol/L plus one
of the biochemical progression or radiological progression¹².

171 Somatic mutations calling

172 Somatic mutations including single nucleotide variants (SNVs) and small-scale 173 insertions/deletions (Indels) were detected using Mutect2 from GATK v4.0.11.0 and Strelka2 v2.8.2¹³. The annotation of the somatic mutations was performed with 174 the ANNOVAR tool ¹⁴. In addition, we used the panel of normals (PoNs) built from 175 the 208 normal samples in the previous study¹⁵ to remove and filter the recurrent 176 177 technical artifacts that mutations appeared in more than one PoN samples. We removed mutations with minor allele frequency > 5% in the NHLBI GO Exome 178 179 Sequencing Project (http://esp.gs.washington.edu), the 1000 Genomes cohort 180 (http://www.internationalgenome.org), and the ExAC resource 181 (http://exac.broadinstitute.org), but retained all COSMIC variants. Mutations within 182 the blacklist that we compiled according to the MutSigCV paper were also filtered and removed¹⁶. Additionally, we also removed variants in repetitive elements 183 (RepeatMasker http://www.repeatmasker.org/) or segmental duplications (UCSC 184 185 hg19.genomicSuperDups). Finally, the candidate mutations in previously 186 implicated cancer genes were reviewed manually on the Integrated Genomics Viewer (IGV) to ensure that no candidate driver mutations were mistakenly 187

188 removed. The correct nomenclature for mutation was checked applying
189 Mutalyzer¹⁷.

190 Somatic copy number alterations calling

We utilized the FACETS v0.5.6 algorithm¹⁸ to detect somatic allele-specific copy 191 192 number alterations (CNA) and determine the tumor purity of the tumor samples 193 from WGS data. The copy number alteration events were defined to meet the following criteria as previously described¹⁹: (1) regions with total copy number = 194 195 3-8 were defined as a gain event; (2) total copy number > 8 were defined as an 196 amplification event; (3) regions with total copy number = 1 were defined as a loss 197 event, and (4) total copy number = 0 were defined as a homozygous deletion event. 198 Additionally, regions with minor copy number = 0 and total copy number > 0 will be 199 defined as a loss of heterozygosity (LOH) event, including LOH (or loss, total copy 200 number = 1), CN-LOH (Copy neutral loss of heterozygosity, total copy number = 2) 201 and Gain-LOH (Copy gain loss of heterozygosity, total copy number > 2).

202 Genetic clone evolution analysis and driver events annotating

PyClone²⁰, an algorithm to infer clonality by the Bayesian clustering method, was conducted to reconstruct the accurate clonal and subclonal architecture across primary and metastatic tumors. The somatic mutations with depth higher than 30× for WGS and 100X for WES were used as input to PyClone. Using the Bam-readcount v0.8.0 (https://github.com/genome/bam-readcount) with minimum base guality 20, we calculated the reference and alternate read-depth of each

209	mutation from the BAM files. To infer cancer cell fraction (CCF) and cluster
210	mutations, PyClone beta-binomial model with the "parental_copy_number" and
211	"tumor_contents" option was run for 50,000 iterations. Clusters containing two or
212	fewer variants were discarded. Mutations clusters identified were imported into
213	ClonEvol ²¹ to track and visualize tumor's clonal evolution (Supplementary Table
214	S2). The potential driver events for somatic mutations and CNA were annotated as
215	described previously ¹⁹ . Driver gene mutations were labeled in clonal evolution
216	trees according to the results of ClonEvol, and the driver CNA events were labeled
217	by matching the presence/absence status of the copy number events with that of
218	the clusters across samples. The body map was drawn by referring the study of
219	Gunes Gundem et al ²² .
220	Analysis for Intratumor heterogeneity of DNA methylation
221	Methylation calls and differentially methylated cytosines were analyzed using R
222	package methylKit v1.2.0 ²³ . No batch effects were identified by assocComp in
223	methylKit and there were no plating issues. The top 1% of CpG sites (n=150,000)

223 methylKit and there were no plating issues. The top 1% of CpG sites (n=150,000) 224 with the greatest intratumoral methylation range were selected for downstream 225 analysis. Clustered heatmaps were drawn using the superheat package 226 (https://github.com/rlbarter/superheat), and Euclidean distance was calculated for 227 hierarchical clustering. We calculated the DNA methylation variability²⁴, which was 228 defined by the median of the range of CpG sites, to measure the intratumoral 229 heterogeneity of methylation in genomic contexts. The higher the methylation

p12

variability represents the more ITH observed. The CpG annotation reference was
obtained from the R package annotatr (https://github.com/hhabra/annotatr).
Methylation levels at least 20% increase/decrease relative to the average of
normal samples were defined as hyper- methylation and hypo-methylation,
respectively.

235 **Reconstruction of methylation and mutation-derived phylogenetic tree**

236 We performed the dist function in the R to generate DNA methylation Euclidean 237 distance matrices using the top 1% of CpG sites with the greatest intratumoral 238 methylation range. The mutation Euclidean distance matrices were calculated 239 using the CCF or VAF of mutations that were input to ClonEvol, and the mutations 240 private to PB2 and LV2M were removed. The fastme.bal function in the R package 241 ape²⁵ was used to reconstruct the Euclidean distance matrices-based phylogenetic 242 tree by applying the minimal evolution algorithm. Confidence for the branches on 243 phylogenetic trees was assessed by bootstrapping (1,000 bootstrap replicates) 244 using the boot.phylo function in the R package ape. Congruence between the 245 genetic and epigenetic distance matrices was calculated by the Spearman's 246 correlation coefficient.

247 More detailed methods are provided in Supplementary Materials and Methods.

248 <u>Results</u>

249 **Program development: the warm autopsy in China**

p13

250 To gain insight into the intratumor heterogeneity and evolutionary mechanisms 251 during tumor metastasis and drug resistance, we established the Changhai Warm 252 Autopsy Team (CWAT), a multidisciplinary team, to recruit cancer patients close to 253 the end of life and perform warm autopsies for tumor sampling in disseminated 254 disease (Fig 1). The team was consisted of urologists, general surgeons, 255 orthopedists, cardiothoracic surgeons and neurosurgeons for harvesting all normal 256 and cancer tissues; blood bank technicians for blood collection; additional 257 members responsible for tissue processing and labeling; pathologists for 258 pathology review and translation medicine center personnel for research and data 259 analysis. All team members were permanent employees and were available 260 round-the-clock. The warm autopsy committee approved the protocol, procedures, 261 and methods for obtaining informed consent. In Fig 1 we diagramed the warm 262 autopsy operation station, which contained 6 independent collection areas for the 263 tissue procurement and storage. The unique identifier of each sample was 264 assigned during autopsy. All clinicopathologic information related to the patient's 265 medical and surgical history, medications, imaging studies, pathology and autopsy findings were deposited in a follow-up database PC-Follow^{TM 26}. 266

267 P

Patient information and tissue collection

The subject was diagnosed with prostate adenocarcinoma, and received androgen deprivation therapy (ADT) combined with systemic chemotherapy right after primary diagnosis (Fig 2A). However, an elevated prostate specific antigen (PSA)

p14

271 level and multiple metastases detected by imaging indicated disease progression 272 to metastatic castration-resistant prostate cancer (mCRPC) in July 2016. To assess 273 tumor progression, ADT combining chemotherapy was discontinued, and the 274 metastasis was found at left supraclavicular and right pelvic lymph nodes by 275 ultrasound-guided needle biopsy. Targeted seguencing was performed in plasma 276 samples using a custom gene panel for ctDNA (circulating tumor DNA), and 277 Vemurafenib therapy was applied based on the discovery of the BRAF V600E 278 mutation. The allele fraction (AF) of BRAF mutation decreased during targeted 279 therapy (Supplementary Fig 1). After a slight improvement in the patient's condition, 280 dyspnea and renal insufficiency began to appear in December 2016. Despite 281 systematic support, the patient succumbed to multiple organ failure in January 282 2017. After death, the tumor tissues from eight metastatic sites and normal tissues 283 from 23 anatomic sites were procured and stored by warm autopsy (Fig 2B). The 284 autopsy was completed in a total of 2.5 hours, and performed as outlined in 285 "Methods".

In this patient, the autopsy revealed widely disseminated prostate tumors in bladder, peritoneum, seminal vesicles, lymph nodes and bones (Fig 2B, Supplementary Fig 2A). Among them, we observed that the chains of lymph nodes were involved by metastatic spread, and the retroperitoneal and supraclavicular lymph nodes were two obvious sites of metastasis. Additionally, we identified additional metastases through autopsy and pathological review; however, due to

p15

the limited sample size and ethical considerations, we did not retain them for further analysis (Supplementary Fig 2B). In addition to common metastatic sites of prostate cancer such as the adrenal gland and liver^{27,28}, we also identified the metastatic cancer thrombus in quadriceps femoris muscle and inferior vena cava, and skin metastases (Supplementary Fig 2B). These rare and atypical metastatic foci highlight the complexity of prostate cancer dissemination.

298 To determine the genetic and epigenetic heterogeneity and metastatic progression 299 of cancer that gave rise to the lethal tumor burden, high guality tumor samples 300 collected across different clinical courses were profiled using multi-omics 301 approaches including whole genome sequencing (WGS), whole-exome 302 sequencing (WES), whole-genome bisulfite sequencing (WGBS) and RNA 303 sequencing (RNA-seq) (Fig 2C, D). In total, 11 tumor samples and one 304 non-cancerous matched healthy prostate tissue were collected for sequencing. 305 The tumor samples included three treatment naïve tumor specimens were 306 obtained from prostate FFPE biopsy, and eight metastases from warm autopsy 307 (Fig 2D). To describe the heterogeneity of primary tumor, we performed WGS on 308 four prostate samples. Limited by the small size of the puncture tissue, however, 309 we only selected an adequate sample (PB2) for additional WES and RNA-seq. For 310 seven metastases samples, we performed WGS, WES, WGBS and RNA-seg to 311 dissect the evolutionary progression, while bone samples (LV2M) only performed 312 WGS due to the small sample size (Supplementary Table S1).

313 Intratumoral genetic heterogeneity of prostate primary tumors

314 To characterize the genetic origin and subclonal architecture of primary tumors, 315 we analyzed WGS data of three biopsy samples at the time of initial diagnosis (Fig 316 2C). Due to the relatively low tumor purity (34%) of sample PB2 estimated by WGS, 317 we further performed ultra-deep WES (1,119X) on this sample. All 3 318 treatment-naïve tumors shared widespread somatic mutations, including TP53 319 p.(Asn179Glnfs*26) and CDK12 p.(Ala993Val) (Fig 3A) that have been 320 demonstrated to be frequently mutated in previously characterized metastatic prostate cancer cohorts^{29,30}. To determine the clonality of somatic mutations, we 321 322 further calculated the AF distributions (Fig 3B). Remarkably, the TP53 and CDK12 323 mutations had the largest allele frequencies which matched each tumor sample's 324 purity, suggesting that these mutations are clonal and present in almost all tumor 325 cells. Copy number alteration (CNA) analysis revealed that all three samples 326 underwent loss of heterozygosity (LOH) of TP53 and CDK12, resulting in complete 327 inactivation of these known prostate cancer genes (Fig 3C). Utilizing the somatic mutations as a molecular clock as described previously³¹, we explored the 328 329 sequential accumulation of LOH events of these two driver mutations (Fig 3D). For 330 example, the TP53 mutation clearly occurred before the 17p copy neutral loss of 331 heterozygosity (CN-LOH), as it was present on both copies of chromosome 17p. 332 Although it's hard to infer the exact order of CDK12 mutation and one copy loss of 333 chromosome 17q11.2-21.2 by existing algorithms, the conclusion of CDK12 and

334 *TP53* mutation occurred before tumor clonal expansions could be drawn.

335	Next we determined the clonal relationship between tumor cell subpopulations. We
336	calculated the cancer cell fractions (CCF) of mutations between pairs of samples,
337	and constructed the clonal evolution tree based on somatic mutations using the
338	previously published methods (Fig 3E, F). We identified subclonal mutations
339	private to each of the three primary tumors, all were seeded directly from the most
340	recent common ancestor (MRCA) harboring the TP53 and CDK12 alterations. If we
341	used the number of mutations in the corresponding subclones to represent branch
342	lengths in the evolution tree, we found that subclone of the PB3 tumor acquired
343	significantly more mutations than PB1 and PB2 (Fig 3A, F). However, examining
344	the mutational signature of PB3 did not reveal meaningful interpretations for this
345	anomaly (Supplementary Fig 3). Manual review of these mutations confirmed that
346	they are true positive mutations for PB3, and not false negatives for PB1 or PB2.
347	This result highlights the intratumoral heterogeneity of primary prostate tumor.
348	Overall, we observed inactivation events of TP53 and CDK12 genes in early tumor
349	evolution stage, suggesting that they are driver events for the origin of prostate
350	cancer in this patient.
351	Intratumoral genetic heterogeneity of prostate metastatic tumors
352	Warm autopsy could provide an invaluable resource to determine the

352 warm autopsy could provide an invaluable resource to determine the 353 mutational landscape and cancer evolution from localized tumor to metastatic 354 tumors, and to reveal potential treatment targets. To understand the genomic

355 intratumoral heterogeneity, we applied stringent alterations calling pipelines 356 including somatic mutations and copy number alterations (CNAs) using WGS 357 data from all sequenced samples (Fig 2D). In total, an average of 96 (25–238) 358 and 57 (41-120) nonsynonymous mutations were detected in primary and metastatic tumors, respectively (Fig 4A). At the CNA level, an average of 98 359 360 (31-213) gains or amplifications, 38 (8-68) losses or deletions and 23 (8-62) 361 CN-LOHs were detected. The average tumor purities of all samples were 0.60 (0.34-0.78) as estimated by FACETS¹⁸. We defined the driver events (Fig 4B, 362 363 Supplementary Table S3) for each tumor using previously established methods¹⁹. In addition to the clonal mutations in CDK12 and TP53, 364 365 amplification of the AR gene was observed in all metastatic samples which 366 could contribute to castration resistance (Fig 4B). Intriguingly, a truncating 367 mutation of CDKN1B p.(Gly97Valfs*22) private to all metastases except for 368 bone sample (LV2M) was identified and validated (Supplementary Fig 4). These 369 findings suggested that the truncated CDKN1B may be a potential driver for 370 tumor lymphatic metastases and periprostatic organ invasion. We also 371 conducted preliminary data analysis and experimental verification in the 372 subsequent section.

To infer the clonal architecture in tumor metastasis, we utilized mutation and CNA information from WES data which had higher depth to perform clonal evolution analysis. We selected 285 somatic mutations detected by both WGS

376 and WES (except for LV2M) as input to PyClone²⁰ and identified 11 major 377 clusters by calculating the CCF and clustering (Supplementary Fig 5). The clonal ordering and a phylogenetic tree were constructed by ClonEvol²¹, which 378 379 determined the clonal relationship among tumors (Fig 4C). We observed the 380 tumor metastasis underwent approximately three processes that are distinctly 381 histologically characterized. The tumor was first metastasized to the bone 382 (LV2M), and then spread to the lymph nodes (SCLN, RMLN, and MSLN) in turn 383 after acquiring the metastatic dominant mutation of CDKN1B, and finally 384 invaded the adjacent organs of the prostate (PMI, BDI, and SVI). The "body 385 maps" were created to characterize the order of driver events and movement of 386 subclones from primary tumor to metastasis (Fig 4D). Metastasis to bone was 387 directly seeded by MRCA, suggesting that LV2M may appear early in systemic 388 disease with a distinct pathway from other metastases. 389 To summarize, from a genetic and molecular perspective, tumor metastases in this 390 case was primarily driven by CDKN1B mutations, but bone metastasis was

391 characterized by an entirely different evolutionary process harboring *FUS*392 mutation.

393 CDKN1B alterations in prostate cancer metastasis

To delineate the genomic alteration atlas of *CDKN1B* in prostate cancer, we preliminarily checked alterations of *CDKN1B* in prostate cancer cohorts from Cbioprotal (https://www.cbioportal.org/). Among a total of 9510 prostate cancer

p20

397 patients, approximately 4% exhibited variations in the CDKN1B gene, which 398 were predominantly truncated mutations and deep deletions (Supplementary 399 Fig 6A). We checked the mutational spectrum, and found the CDKN1B mutation 400 p.(Gly97Valfs*22) detected in this case were also identified by the metastatic prostate cancer cohort MSK³² (Fig 5A). Importantly, we observed the mutation 401 402 was located within a hot spot (amino acids 83-102), which specifically enriched in the metastatic patients. Even though we did not obtain statistically significant 403 404 results, these findings still indicated that hot spot mutations represented by 405 p.(Gly97Valfs*22) may be driver events leading to prostate cancer metastasis. Furthermore, using RNA-seq data from this warm autopsy patient and 406 previously published CPGEA cohort¹⁵, we found that the RNA expression of 407 408 CDKN1B was down-regulated in metastases (truncating) compared with primary tumor samples (Supplementary Fig 6B). The pattern was further 409 validated by using TCGA public data³³ (Supplementary Fig 6C). These results 410 411 implied that the genomic variations (truncating or deletion) of CDKN1B could 412 lead to down-regulation of expression and promote the metastasis of prostate 413 cancer.

To explore the function of the down-regulation of *CDKN1B* expression, we designed and synthesized two sets of shRNA sequences and one set of control shRNA sequences. The cell line 22RV1 was chosen in all subsequent experiments due to the highest expression of *CDKN1B* (Supplementary Fig 7)

p21

and originating from primary prostate cancer. We observed that the migration
and invasion abilities in the *CDKN1B* downexpression group was significantly
increased when compared with the control group (Fig 5B, C and D,
Supplementary Fig 7). Taken together, the results suggested that the
down-regulation of *CDKN1B* may be involved in metastasis of prostate cancer.

423 Intratumor heterogeneity of DNA methylation and epigenomic evolution

424 Our previous study demonstrated the congruence of genomic and epigenomic tumor evolutionary histories in a large population¹⁵. To comprehensively dissect 425 426 the epigenetic clonal evolution of tumor metastases, we applied genome-wide 427 DNA methylation analysis from seven metastatic samples in this case (Fig 2D). The WGBS data of three normal prostate specimens from a previous study³⁴ were 428 429 used as the reference prostate epigenome in this analysis (Supplementary Fig 8A, 430 B). By using the 1% of CpG sites with the greatest intratumoral methylation 431 variation for unsupervised clustering analysis, we observed the overall 432 hypomethylation patterns in tumor samples and the extensive epigenetic 433 heterogeneity across anatomically distinct metastasis samples (Fig 6A). To define 434 the signatures of DNA methylation heterogeneity, we examined the genomic 435 context of the CpG sites with the most variable methylation levels across samples. 436 The variable sites within tumors were not distributed evenly across the genome. 437 but were enriched in CpG islands and promoters, which showed greater 438 intratumoral heterogeneity than other genomic features examined (Fig 6B).

p22

439 The highly dynamic genetic alterations and the extensive epigenetic heterogeneity 440 across metastases prompted us to investigate the association between genetics 441 and epigenetics during tumor evolution. We constructed a phylogenetic tree based on DNA methylation levels across samples²⁴. The epigenetic phylogenetic tree 442 443 almost superimposed the genetic tree constructed based on genetic mutation data 444 in their topology (Fig 6C, Fig 4C, Supplementary Fig 8D). To quantify the 445 resemblance between somatic mutation and DNA methylation based phylogenetic 446 trees, we used variant allele fraction and cancer cell fraction to calculate the 447 Euclidean distance and constructed the genetic evolution trees, respectively (Fig 448 6D). In addition to CCF showing a phylogenetic relationship almost consistent with 449 methylation, we also confirmed the congruence between epigenetic and genetic 450 evolution by calculating the Spearman correlation coefficient for distance matrices 451 (Fig 6E). Finally, we defined the hyper- and hypo-methylation of CpG island in 452 promoter region of known prostate cancer driver genes, and investigated which 453 genes were affected by methylation events (Fig 6F, Supplementary Fig 8C). We 454 observed that some genes that have been verified to be frequently altered in DNA 455 methylation in prostate cancer, such as GSTP1, AOX1 and CCDC68^{15,35,36}, were 456 hypermethylated in all metastases in this patient, indicating that they were likely 457 clonal events and may occur earlier in prostate cancer evolution. Together, we 458 showed the extensive epigenetic heterogeneity across prostate cancer metastases,

p23

459 which displayed a phylogenetic relationship recapitulating the genetic clonal460 evolution.

461 **Discussion**

462 The development of warm autopsy program empowered the investigators with the 463 unprecedented ability to thoroughly sampling and comprehensively dissect the evolutionary trajectories of metastatic-lethal prostate cancer^{7,22,37,38}. Warm autopsy 464 465 program now has been implemented in various types of research facilities: 466 non-profit research institutes, universities and federal research institutes in America^{7,10}, Spain³⁹, England⁴⁰, Australia⁴¹, etc. However, protocols and 467 468 guidelines for warm autopsy have been individually modified according to the policies of different countries, such as ethics⁹, standard operation procedures⁸ and 469 difficulties in practice^{5,10}. 470

471 Despite the potential benefits of warm autopsy, the barriers and restrictions in 472 implementation and development have limited the number of autopsies in cancer patients, especially in China⁴². Due to the traditional concept of preserving the 473 474 intact body after death, the development of the body donation and autopsy system in China has been relatively slow ⁴³. The societal and community resistance are 475 476 generally derived from concerns regarding body disfigurement after the autopsy, 477 unwillingness from the patient's families, and a lack of awareness towards the 478 practice of autopsy. The logistical challenges not only require researchers to build 479 a multi-departmental team, but also to have access to round-the-clock services for

preservation of tissue integrity⁴⁴. Additional consideration includes legal
requirements and ethics guidelines governing consent for autopsy procedures,
and the lack of awareness of warm autopsy among academic oncologists or
investigators⁴⁵.

484 In this study, we preformed, to our knowledge, the first warm autopsy program in 485 China. Through multidisciplinary teamwork, we collected eight metastatic tissues 486 from a mCRPC patient throughout the warm autopsy within 2.5 hours after death. 487 We comprehensively depicted the genetic and epigenetic cancer clonal evolution, 488 and dissected the heterogeneous dynamics of the metastatic process of prostate 489 cancer in this patient. Furthermore, we found that there was a hot spot in CDKN1B, 490 which may be an important driver event to promote prostate cancer metastasis. 491 The protein p27Kip1, encoded by CDKN1B, could inhibit tumor cell migration and invasion by binding to stathmin⁴⁶. When *CDKN1B* was truncated, the loss of 492 493 stathmin binding region (amino acids 170-198) and downregulation of expression may be the mechanism that promotes tumor metastasis⁴⁷. In prostate cancer, the 494 495 predominant variant types of CDKN1B were truncating mutation and deep deletion, which have been associated with increased risks of metastasis^{48,49}. Finally, the 496 497 metastatic phylogenetic tree we constructed further supported the previous viewpoint that genetics and epigenetics are concordant in tumor evolution^{24,50,51}. 498 499 The Changhai Warm Autopsy Team (CWAT) was dedicated to collect samples 500 from end-stage disease and identify resistant and metastatic mechanisms of

p25

501 cancer. With the support of CWAT, here, we not only performed warm autopsy, but 502 also explored and established the internationally accepted standards in cancer 503 field in China. This study and the warm autopsy program have important clinical 504 and research implications. Our previous work in building the Chinese Prostate 505 Cancer Genome and Epigenome Atlas revealed genomic and epigenomic 506 signatures that were distinct from those of Western patients^{15,33}. Investigating how 507 such signatures evolve during tumorigenesis and metastasis can be critical to the 508 understanding of disease mechanism and development of therapy. Warm autopsy 509 provides an important platform to collect appropriate specimens for achieving the goal of reconstructing the steps of tumour evolution from initiation to metastasis⁵². 510 511 Moving forward, we will initiate warm autopsy programs in large cohorts, conduct 512 no fewer than 10 warm autopsies per year. Meanwhile, we are designing clinical 513 trials to integrate longitudinal genomic and epigenomic studies to track cancer resistance and dissemination, following the TRACERx Consortium model^{53,54}. 514 515 Furthermore, we have initiated programs to raise awareness of warm autopsy 516 among patients, their relatives, and the general public.

517 Conclusions

518 We performed the first warm autopsy in China. We call on Chinese urologists and 519 oncologists to promote warm autopsy of prostate cancer. We found the driver gene 520 *CDKN1B* that is associated with the metastasis of prostate cancer, and the 521 mechanism of this gene's role in metastasis awaits further investigation. We also

delineated the congruence of genetic and epigenetic clonal evolution during tumor

metastasis. In conclusion, the warm autopsy process and standard and analysis

522

523

p26

524	pipelines we have established will pave the way for more investigators to apply								
525	them to the clinical diagnosis and treatment of prostate cancer.								
526	Data availability								
527	The sequencing data in BAM format are available at the Genome Sequence								
528	Archive (GSA) for Human at the BIG Data Center								
529	(http://bigd.big.ac.cn/gsa-human/), Beijing Institute of Genomics with the								
530	accession number PRJCA010385.								
531	Acknowledgements								
532	We sincerely thank the patient and his family. We wish to expressly thank								
533	Zhengmao Lu (Department of General Surgery), Changwei Yang (Department of								
534	Orthopaedic Surgery), Yuan Zou (Department of Neurosurgery), Chenguang Li								
535	(Department of Cardiothoracic Surgery) and Yeqing Lu (Operating Room) for the								
536	critical help implementing the warm autopsy. We would like to thank Guiling Ding								
537	(Department of Pathology) and Cong Wu (Biological Sample Bank) for								
538	coordinating the pathology review, tissue processing and labeling.								
539	Funding information								
540	This work was supported by the Promote Clinical Skills and Innovation Ability of								
541	Municipal Hospitals Project (SHDC2020CR6007), Shanghai Rising-Star Program								
542	(20QA1411800) and National Natural Science Foundation of China (82022055).								

543 Authors' contributions

- 544 Conceptualization, XG and JL; Formal Analysis, WZ, TW and ZW; Investigation,
- 545 BL, LC and XY; Writing—Original Draft, WZ and HS; Writing—Review & Editing,
- 546 YW, MQ and XL; Funding Acquisition, XG and JL; Resources, YY, QY and FL;
- 547 Supervision, ZL. All authors read and approved the final manuscript.

548 Ethics approval and consent to participate

- 549 This study was approved by the ethical board at Changhai Hospital (No:
- 550 TMEC2014-001, No: CHEC2019-165). Informed consent was obtained from all
- 551 participants involved in the study, and all experiments were conducted in line with
- the principles of the Declaration of Helsinki.

553 Consent for publication

554 There are no individual person's data from all participants involved in the study.

555 **Conflict of interest**

- 556 The authors declare that they have no competing interests.
- 557

p28

558 **References**

559	1	Kimura, T. East meets West: ethnic differences in prostate cancer epidemiology between
560		East Asians and Caucasians. Chin J Cancer 31, 421-429, doi:10.5732/cjc.011.10324
561		(2012).
562	2	Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589
563		patients. <i>Hum Pathol</i> 31 , 578-583, doi:10.1053/hp.2000.6698 (2000).
564	3	Roudier, M. P. et al. Histopathological assessment of prostate cancer bone osteoblastic
565		metastases. J Urol 180, 1154-1160, doi:10.1016/j.juro.2008.04.140 (2008).
566	4	Harris, C. C. et al. Binding of (3H)benzo(a)pyrene to DNA in cultured human bronchus.
567		<i>Cancer Res</i> 36 , 1011-1018 (1976).
568	5	Lindell, K. O., Erlen, J. A. & Kaminski, N. Lessons from our patients: development of a
569		warm autopsy program. PLoS Med 3, e234, doi:10.1371/journal.pmed.0030234 (2006).
570	6	Bidaut-Russell, M., Dowd, D. M., Grossberg, G. T. & Zimny, G. H. Survey of U.S. Alzheimer
571		Brain Banks: a 1990 directory. Alzheimer Dis Assoc Disord 5, 188-193 (1991).
572	7	Rubin, M. A. et al. Rapid ("warm") autopsy study for procurement of metastatic prostate
573		cancer. <i>Clin Cancer Res</i> 6 , 1038-1045 (2000).
574	8	Carithers, L. J. et al. A Novel Approach to High-Quality Postmortem Tissue Procurement:
575		The GTEx Project. Biopreserv Biobank 13, 311-319, doi:10.1089/bio.2015.0032 (2015).
576	9	Pentz, R. D. et al. Ethics guidelines for research with the recently dead. Nat Med 11,
577		1145-1149, doi:10.1038/nm1105-1145 (2005).
578	10	Shah, R. B. et al. Androgen-independent prostate cancer is a heterogeneous group of
579		diseases: lessons from a rapid autopsy program. Cancer Res 64, 9209-9216,
580		doi:10.1158/0008-5472.CAN-04-2442 (2004).
581	11	Carithers, L. J. & Moore, H. M. The Genotype-Tissue Expression (GTEx) Project.
582		<i>Biopreserv Biobank</i> 13 , 307-308, doi:10.1089/bio.2015.29031.hmm (2015).
583	12	Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced,
584		relapsing, and castration-resistant prostate cancer. Eur Urol 65, 467-479,
585		doi:10.1016/j.eururo.2013.11.002 (2014).
586	13	Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat
587		<i>Methods</i> 15 , 591-594, doi:10.1038/s41592-018-0051-x (2018).
588	14	Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants
589		from high-throughput sequencing data. Nucleic Acids Res 38, e164,
590		doi:10.1093/nar/gkq603 (2010).
591	15	Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature
592		580 , 93-99, doi:10.1038/s41586-020-2135-x (2020).
593	16	Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new
594		cancer-associated genes. <i>Nature</i> 499 , 214-218, doi:10.1038/nature12213 (2013).
595	17	Lefter, M. et al. Mutalyzer 2: next generation HGVS nomenclature checker. Bioinformatics
596		37 , 2811-2817, doi:10.1093/bioinformatics/btab051 (2021).
		• •

p29

597	18	Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity							
598		analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44, e131,							
599		doi:10.1093/nar/gkw520 (2016).							
600	19	Zhang, W. et al. Intratumor heterogeneity and clonal evolution revealed in							
601		castration-resistant prostate cancer by longitudinal genomic analysis. Transl Oncol 16,							
602		101311, doi:10.1016/j.tranon.2021.101311 (2022).							
603	20	Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat							
604		<i>Methods</i> 11 , 396-398, doi:10.1038/nmeth.2883 (2014).							
605	21	Dang, H. X. et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann							
606		Oncol 28 , 3076-3082, doi:10.1093/annonc/mdx517 (2017).							
607	22	Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520,							
608		353-357, doi:10.1038/nature14347 (2015).							
609	23	Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide							
610		DNA methylation profiles. Genome Biol 13, R87, doi:10.1186/gb-2012-13-10-r87 (2012).							
611	24	Brocks, D. et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in							
612		aggressive prostate cancer. Cell Rep 8, 798-806, doi:10.1016/j.celrep.2014.06.053 (2014).							
613	25	Desper, R. & Gascuel, O. Fast and accurate phylogeny reconstruction algorithms based on							
614		the minimum-evolution principle. J Comput Biol 9 , 687-705,							
615		doi:10.1089/106652702761034136 (2002).							
616	26	Sun, X. G. H. W. Y. W. C. X. Y. Construction and clinical application of prostate cancer							
617		database (PC-Follow) based on browser/server schema. Chinese Journal of Urology 36,							
618		694-698 (2015).							
619	27	Gandaglia, G. et al. Distribution of metastatic sites in patients with prostate cancer: A							
620		population-based analysis. <i>Prostate</i> 74 , 210-216, doi:10.1002/pros.22742 (2014).							
621	28	Gandaglia, G. et al. Impact of the Site of Metastases on Survival in Patients with Metastatic							
622		Prostate Cancer. <i>Eur Urol</i> 68, 325-334, doi:10.1016/j.eururo.2014.07.020 (2015).							
623	29	Quigley, D. A. et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate							
624		Cancer. <i>Cell</i> 174 , 758-769 e759, doi:10.1016/j.cell.2018.06.039 (2018).							
625	30	Reimers, M. A. et al. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced							
626		Prostate Cancer. <i>Eur Urol</i> 77 , 333-341, doi:10.1016/j.eururo.2019.09.036 (2020).							
627	31	Yang, L. et al. An enhanced genetic model of colorectal cancer progression history.							
628		Genome Biol 20 , 168, doi:10.1186/s13059-019-1782-4 (2019).							
629	32	Stopsack, K. H. et al. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes							
630		in Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res 26, 3230-3238,							
631		doi:10.1158/1078-0432.CCR-20-0168 (2020).							
632	33	Cancer Genome Atlas Research, N. The Molecular Taxonomy of Primary Prostate Cancer.							
633		<i>Cell</i> 163 , 1011-1025, doi:10.1016/j.cell.2015.10.025 (2015).							
634	34	Wang, T. et al. Integrative Epigenome Map of the Normal Human Prostate Provides							
635		Insights Into Prostate Cancer Predisposition. Front Cell Dev Biol 9, 723676.							
636		doi:10.3389/fcell.2021.723676 (2021).							

637	35	Henrique R & Jeronimo C Molecular detection of prostate cancer: a role for GSTP1						
638	55	hypermethylation Fur I rol 46, 660, 660; discussion 660, doi:10.1016/i.ourure.2004.06.014						
639		(2004)						
640	36	Li W et al Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival Fur						
641	00	<i>Lirol</i> 74 , 710-719, doi:10.1016/i eururo.2018.06.021 (2018)						
642	37	Haffner M C et al. Tracking the clonal origin of lethal prostate cancer . I Clin Invest 123						
643	01	4918-4922, doi:10.1172/JCI70354 (2013).						
644	38	Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer.						
645		Nature 487, 239-243, doi:10.1038/nature11125 (2012).						
646	39	Xie, T. et al. Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models						
647		Reveals Possible Driver Mutations Underlying Tumor Progression. PLoS One 10,						
648		e0142631, doi:10.1371/journal.pone.0142631 (2015).						
649	40	(https://ClinicalTrials.gov/show/NCT03004755, 2016).						
650	41	Alsop, K. et al. A community-based model of rapid autopsy in end-stage cancer patients.						
651		Nat Biotechnol 34, 1010-1014, doi:10.1038/nbt.3674 (2016).						
652	42	Zhu, M. H. & Yu, D. H. Fluctuations in the rate of autopsy in China. Chin Med J (Engl) 124,						
653		3403-3407 (2011).						
654	43	Zheng, W. Q., Fan, Y. H. & Ng, A. Public attitudes towards the autopsy in China. Pathology						
655		30 , 92-94 (1998).						
656	44	Savas, P. et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a						
657		Prospective Community-Based Rapid Autopsy Program "CASCADE". PLoS Med 13,						
658		e1002204, doi:10.1371/journal.pmed.1002204 (2016).						
659	45	Krook, M. A., Chen, H. Z., Bonneville, R., Allenby, P. & Roychowdhury, S. Rapid Research						
660		Autopsy: Piecing the Puzzle of Tumor Heterogeneity. Trends Cancer 5, 1-5,						
661		doi:10.1016/j.trecan.2018.11.004 (2019).						
662	46	Baldassarre, G. et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and						
663		invasion. Cancer Cell 7, 51-63, doi:10.1016/j.ccr.2004.11.025 (2005).						
664	47	Cusan, M. et al. Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other						
665		Hormone-Driven Human Tumors. Front Endocrinol (Lausanne) 9, 393,						
666		doi:10.3389/fendo.2018.00393 (2018).						
667	48	Faisal, F. A. et al. CDKN1B Deletions are Associated with Metastasis in African American						
668		Men with Clinically Localized, Surgically Treated Prostate Cancer. Clin Cancer Res 26,						
669		2595-2602, doi:10.1158/1078-0432.CCR-19-1669 (2020).						
670	49	Macri, E. & Loda, M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 17,						
671		337-344, doi:10.1023/a:1006133620914 (1998).						
672	50	Zhu, B. et al. The genomic and epigenomic evolutionary history of papillary renal cell						
673		carcinomas. Nat Commun 11, 3096, doi:10.1038/s41467-020-16546-5 (2020).						
674	51	Mazor, T. et al. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and						
675		Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell 28, 307-317,						
676		doi:10.1016/j.ccell.2015.07.012 (2015).						

677	52	Hessey, S., F	essas, P., Za	accaria, S., J	amal-Hanjani,	M. & Swanton,	C. Insights	into the	
678		metastatic	cascade	through	research	autopsies.	Trends	Cancer,	
679		doi:10.1016/j.trecan.2023.03.002 (2023).							
680	53	Bailey, C. <i>et al.</i> Tracking Cancer Evolution through the Disease Course. <i>Cancer Discov</i> 11 ,							
681		916-932, doi:1	0.1158/2159	-8290.CD-20-	-1559 (2021).				

- 54 Jamal-Hanjani, M. *et al.* Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J*683 *Med* 376, 2109-2121, doi:10.1056/NEJMoa1616288 (2017).
- 684

685 Figure Legend

686 Fig. 1 Workflow diagram giving overview of warm autopsy.

687 The four steps of the study are shown on the left. The right shows in detail the

- organization of the warm autopsy committee, as well as the operating table layout
- 689 in implementation.

Fig. 2 Clinical course and serial procurement of the patient.

691 (A) The clinical course of disease progression and treatment in this index case. 692 The bottom figure shows the pathology of biopsies (200x magnification). (B) The 693 pathology of metastatic sites procured by warm autopsy (200x magnification). All 694 the hematoxylin and eosin (H&E) stains were performed using standard 695 techniques. (C) Tissue and blood samples taken at different times. Two lymph 696 node metastases samples taken on day 210 were not sequenced. R, right; L, left; 697 LN, lymph node. (D) The type of sequencing performed. The abbreviations of 698 samples are indicated. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedding.

Fig. 3 Intratumoral genetic heterogeneity of prostate primary tumors.

700 (A) The regional distribution of nonsynonymous mutations in primary tumors. The

heat map indicates the presence of a mutation (purple) or its absence (white) in the

p32

702 individual tumor. Right showed the gene names of driver mutations. The TP53 703 mutation was not detected in the PB2 sample using WGS due to insufficient total 704 depth, and the number in square indicate the alt reads/total reads/allele fraction. 705 (B) The figure shows the allele fraction distributions plotted by mutation number 706 (left vertical axis) and density (right vertical axis). Tumor purity provided by 707 FACETS in three samples is also indicated. (C) Copy number profile of chr17 and 708 the LOH of TP53 and CDK12. Shown from upper to lower are the total copy 709 number log-ratio (the log ratio of total read depth in the tumor versus that in the 710 normal), allele-specific log-odds-ratio (the log odds ratio of the variant allele count 711 in the tumor versus in the normal), and corresponding integer (total, minor) copy 712 number calls provided by FACETS. (D) The figure demonstrates how somatic 713 mutations accumulate in a CN-LOH (TP53) and Loss (CDK12) chromosome. (E) 714 Cancer cell fractions and clusters of mutations inferred by PyClone for pairs of 715 samples. Blue density areas reveal the mutation clusters present at clonal or 716 subclonal levels, and the manually colored circles provide the localization of 717 mutation clusters in different samples. Driver mutation genes present in the cluster 718 are marked in red. (F) The clonal evolution tree of the primary tumor. The length of 719 branches connecting clones is proportional to the number of mutations contained, 720 and the driver events identified are marked on the tree.

Fig 4. Intratumoral genetic heterogeneity and clonal evolution of prostate
 metastatic tumors.

p33

723 (A) An overview of somatic alterations detected in 11 tumors. Each panel displays 724 the number of mutations in coding region, nonsynonymous mutations, the number 725 of segments for copy number alterations, and the tumor purity, respectively. (B) 726 Overview of the analyzed driver genomic alterations in the primary tumor and 727 metastases. (C) The clonal evolution tree of the primary tumor and metastases 728 inferred by ClonEvol. Except for cluster 12 private to LV2M, which is manually 729 added, all the CCF clusters were calculated by PyClone. The branch length is 730 scaled by the log2 ratio of the number of mutations in the individual clone. The 731 potential driver events are highlighted. (D) The emergence and movement of 732 clones in the spread of metastasis. The color-coded arrows depict the seeding 733 events and the acquisition of mutations, and the sequence of events is ordered 734 according to the clonal evolution relationship. Plus (+), the acquisition of subclone.

735 **Fig 5.** *CDKN1B* alterations in prostate cancer metastasis.

(A) The position distribution of *CDKN1B* somatic mutations in this patient and in the deduplicated samples from cbioprotal. The circles are colored with respect to the different mutation types, and the size represents the number of patients with the mutation. (B) Scratch assay of 22RV1 cells transfected with shRNA (n = 3), which corresponds to Supplementary Fig 7D. (C, D) Images of migrating and invading cells tested by using Transwell assays for 22RV1 cells transfected with shRNA (n = 3). *P* values were determined by two-tailed Student's t test.

743 Fig 6. Intratumor heterogeneity of DNA methylation and epigenomic

744 evolution in prostate metastatic tumors.

745 (A) The figure shows the intratumoral heterogeneity of methylation patterns 746 depicted by unsupervised hierarchical clustering using the top 1% of CpG sites (n 747 = 150,000) with the greatest difference. Normal samples were excluded for the 748 hierarchical clustering but were input into row clustering. (B) DNA methylation 749 Intratumor heterogeneity on genomic regions. The median methylation variability 750 on the right of the figure was calculated by the range of CpG sites (maximum level 751 - minimal level) between tumors. (C) Epigenomic clonal evolution tree inferred from 752 DNA methylation distance matrices. Lengths of trunks and branches were inferred 753 using the top 1% of CpG sites (same as Fig 5A, see Supplemental Methods). Color 754 coding is the same as in Fig 4F. (D) Genomic clonal evolution tree inferred from 755 CCF (cancer cell fraction, left) and VAF (variant allele fraction, right) distance 756 matrices. (E) The correlation between epigenomic distance matrices and genomic 757 distance matrices (CCF, left; VAF, right). LOESS fitted curve and 95% confident 758 interval are presented. Rho coefficient (R) and P value (P) are assessed by 759 Spearman's rank correlation. (F) The difference in methylation levels of CpG island 760 in promoter region of known prostate driver cancer genes 761 (www.genome.jp/pathway/ko05215) between each tumor and three normal 762 prostate samples. Hyper-methylation and hypo-methylation were defined as 763 difference of more than 20%. White cells in the heatmap represent differences 764 below 20%.



Fig. 1 Workflow diagram giving overview of warm autopsy.

The four steps of the study are shown on the left. The right shows in detail the organization of the warm autopsy committee, as well as the operating table layout in implementation.



Fig. 2 Clinical course and serial procurement of the patient.

(A) The clinical course of disease progression and treatment in this index case. The bottom figure shows the pathology of biopsies (200x magnification). (B) The pathology of metastatic sites procured by warm autopsy (200x magnification). All the hematoxylin and eosin (H&E) stains were performed using standard techniques. (C) Tissue and blood samples taken at different times. Two lymph node metastases samples taken on day 210 were not sequenced. R, right; L, left; LN, lymph node. (D) The type of sequencing performed. The abbreviations of samples are indicated. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedding.



Fig. 3 Intratumoral genetic heterogeneity of prostate primary tumors.

(A) The regional distribution of nonsynonymous mutations in primary tumors. The heat map indicates the presence of a mutation (purple) or its absence (white) in the individual tumor. Right showed the gene names of driver mutations. The *TP53* mutation was not detected in the PB2 sample using WGS due to insufficient total depth, and the number in square indicate the alt_reads/total_reads/allele_fraction. (B) The figure shows the allele fraction distributions plotted by mutation number (left vertical axis) and density (right vertical axis). Tumor purity provided by FACETS in three samples is also indicated. (C) Copy number profile of chr17 and the LOH of *TP53* and *CDK12*. Shown from upper to lower are the total copy number log-ratio (the log ratio of total read depth in the tumor versus that in the normal), allele-specific log-odds-ratio (the log odds ratio of the variant allele count in the tumor versus in the normal), and corresponding integer (total, minor) copy number calls provided by FACETS. (D) The figure demonstrates how somatic mutations accumulate in a CN-LOH (*TP53*) and Loss (*CDK12*) chromosome. (E) Cancer cell fractions and clusters of mutations inferred by PyClone for pairs of samples. Blue density areas reveal the mutation clusters present at clonal or subclonal levels, and the manually colored circles provide the localization of mutation clusters in different samples. Driver mutation genes present in the cluster are marked in red. (F) The clonal evolution tree of the primary tumor. The length of branches connecting clones is proportional to the number of mutations contained, and the driver events identified are marked on the tree.



Fig 4. Intratumoral genetic heterogeneity and clonal evolution of prostate metastatic tumors.

(A) An overview of somatic alterations detected in 11 tumors. Each panel displays the number of mutations in coding region, nonsynonymous mutations, the number of segments for copy number alterations, and the tumor purity, respectively. (B) Overview of the analyzed driver genomic alterations in the primary tumor and metastases. (C) The clonal evolution tree of the primary tumor and metastases inferred by ClonEvol. Except for cluster 12 private to LV2M, which is manually added, all the CCF clusters were calculated by PyClone. The branch length is scaled by the log2 ratio of the number of mutations in the individual clone. The potential driver events are highlighted. (D) The emergence and movement of clones in the spread of metastasis. The color-coded arrows depict the seeding events and the acquisition of mutations, and the sequence of events is ordered according to the clonal evolution relationship. Plus (+), the acquisition of subclone.



Fig 5. CDKN1B alterations in prostate cancer metastasis.

(A) The position distribution of *CDKN1B* somatic mutations in this patient and in the deduplicated samples from cbioprotal. The circles are colored with respect to the different mutation types, and the size represents the number of patients with the mutation. (B) Scratch assay of 22RV1 cells transfected with shRNA (n = 3), which corresponds to Supplementary Fig 7D. (C, D) Images of migrating and invading cells tested by using Transwell assays for 22RV1 cells transfected with shRNA (n = 3). P values were determined by two-tailed Student's t test.



Fig 6. Intratumor heterogeneity of DNA methylation and epigenomic evolution in prostate metastatic tumors.

(A) The figure shows the intratumoral heterogeneity of methylation patterns depicted by unsupervised hierarchical clustering using the top 1% of CpG sites (n = 150,000) with the greatest difference. Normal samples were excluded for the hierarchical clustering but were input into row clustering. (B) DNA methylation Intratumor heterogeneity on genomic regions. The median methylation variability on the right of the figure was calculated by the range of CpG sites (maximum level - minimal level) between tumors. (C) Epigenomic clonal evolution tree inferred from DNA methylation distance matrices. Lengths of trunks and branches were inferred using the top 1% of CpG sites (same as Fig 5A, see Supplemental Methods). Color coding is the same as in Fig 4F. (D) Genomic clonal evolution tree inferred from CCF (cancer cell fraction, left) and VAF (variant allele fraction, right) distance matrices. (E) The correlation between epigenomic distance matrices and genomic distance matrices (CCF, left; VAF, right). LOESS fitted curve and 95% confident interval are presented. Rho coefficient (*R*) and P value (*P*) are assessed by Spearman's rank correlation. (F) The difference in methylation levels of CpG island in promoter region of known prostate cancer driver genes (www.genome.jp/pathway/ko05215) between each tumor and three normal prostate samples. Hyper-methylation and hypo-methylation were defined as difference of more than 20%. White cells in the heatmap represent differences below 20%.